Immuneering (IMRX) Research & Development (2020 - 2026)

Immuneering's Research & Development history runs 7 years deep, the most recent figure standing at $10.6 million for Q1 2026.

• In Q1 2026, Research & Development fell 7.2% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $41.2 million (down 14.54% YoY), while the FY2025 annual figure was $42.0 million, down 12.33% from the prior year.
• Research & Development for Q1 2026 stood at $10.6 million, up from $9.3 million in the prior quarter.
• The five-year high for Research & Development was $14.9 million in Q4 2024, with the low at $8.0 million in Q2 2022.
• The 5-year median for Research & Development is $10.5 million (2025), against an average of $10.5 million.
• The sharpest annual moves came in 2022 and 2025: Research & Development jumped 68.03% in 2022, then slumped 37.71% in 2025.
• Immuneering's Research & Development stood at $9.9 million in 2022, then increased by 20.65% to $11.9 million in 2023, then rose by 24.74% to $14.9 million in 2024, then plunged by 37.71% to $9.3 million in 2025, then climbed by 15.03% to $10.6 million in 2026.
• Business Quant data shows IMRX's Research & Development at $10.6 million in Q1 2026, $9.3 million in Q4 2025, and $10.9 million in Q3 2025.